Evaluation of selected serum protein markers as early detectors of ovarian cancer;Ocena możliwości wczesnej diagnostyki raka jajnika na podstawie oznaczeń wybranych białek surowicy

Ginekologia Polska

Volumn 79, Issue 4, 2008, Pages 271-275

  Mrochem, Jolanta ^a   Sodowski, Krzysztof ^b   Deja, Regina ^a   Walaszek Gruszka, Aneta ^c   Wojcieszek, Andrzej ^a   Kołosza, Zofia ^a   Chmura, Aleksandra ^a   Czernik, Ewa ^a   Masłyk, Barbara ^a   Bartnik, Wiesława ^a   Cnota, Wojciech ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Uniwersytetu Medycznego we Wroc awiu   (Poland)

^c NONE   (Poland)

Author keywords

Ca 125; Insulin growth factor II; Leptin; Osteopontin; Ovarian neoplasms; Prolactin

Indexed keywords

CA 125 ANTIGEN; IGF2 PROTEIN, HUMAN; LEPTIN; OSTEOPONTIN; PROLACTIN; SOMATOMEDIN B; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; POLAND; PROSPECTIVE STUDY; REFERENCE VALUE; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; CA-125 ANTIGEN; EARLY DIAGNOSIS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LEPTIN; MIDDLE AGED; OSTEOPONTIN; OVARIAN NEOPLASMS; POLAND; PROLACTIN; PROSPECTIVE STUDIES; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 47749084216     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schwartz D.R, Kardia S.L, Shedden., (et al.) Cancer Res. 2002, 62, 4722-4729
2. Lu K, Patterson A, Wand L, (et al.). Selection of Potential markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis. Clin. Cancer Res. 2004, 10, 3291-3300.
3. Mor G, Visintin I, Lai Y, (et al.). Serum protein markers for early detection of ovarian cancer. PNAS 2005, 102, 21, 7677-7682.
4. Rosen DG, Wang L, Atkinson JN, (et al.) Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol. Oncol. 2005, 2, 267-277.
5. Bast RC Jr, Badgwell D, Lu Z, (et al.). New tumor markers and beyond. Int J Gynecol Cancer 2005, 15, 274-281
6. Palmer C, Pratt J, Basu B, Earl H. A study to evaluate the use of CA 125 in ovarian cancer follow-up: A change in practice led by patient preference. Gynecol. Oncol, 2006, 101, 4-11.
7. Niloff JM, Klug TL, Schaetzl E, (et al.). Elevation of Serum CA 125 in Carcinomas of the Fallopian Tube, Endometrium and Endocervix. Am J Obstet. Gynecol. 1984, 148, 1057-1058
8. Ruibal A, Encabo G, Miralles EM, (et al.). CA 125 Seric Levels in Non Ovarian Pathologies. Pergamon Press 1984, 613-616
9. Barbieri RL, Niloff JM, Bast RC Jr, (et al.) Elevated Serum Concentrations of CA 125 in Patiens with Advances Endomertiosis. Fertil Steril 1986, 45, 630-634
10. Pittaway DE. Ca 125 in Women with Endometriosis. Obstet. Gynecol. Clin. North A. 1989, 16(1), 237-252.
11. Takahashi K, Kijima S, Yoshino K, (et al.). Serum Ca 125 as a Marker for Patients with External Endometriosis. Int J Fertil 1989 34 (2), 143-148.
12. Guidice LC, Jacobs A, Pineda J, (et al.). Serum Levels of CA 125 in Patients with Endometriosis: A Preliminary Report. Fertil Steril 1986, 45(6), 876-878.
13. Masahashi T, Matsuzawa K, Ohsawa M, (et al.). Serum CA 125 Levels in Patients with Endometriosis: Changes in CA 125 Levels During Menstruation. Obstet. Gynecol. 1988, 72(3), 328-331.
14. Malkasian GD Jr, Podratz KC, Stanhope CR, (et al.) CA 125 in Gynecologic Practice. Am J Obstet. Gynecol. 1988, 155, 515-518.
15. Niloff JM< Knap RC, Schaetzl E, (et al.) CA 125 Antigen Levels in Obstetric and Gynecologic Patients. Obstet. Gynecol. 1984, 64, 703-707
16. Halila H, Stenman UH, Seppala M. Ovarian Cancer Antigen CA 125 Levels in Pelvic Inflammatory Disease and Pregnancy. Cancer 1986, 57, 1327-1329.
17. Kabawat SE, Bast RC Jr, Bhan AK, (et al.) Tissue Distribution of a Coelomic-Epithelium-Related Antigen Recognized by the Monoclonal Antibody OC 125. Int J Gynecol. Pathol. 1983, 2, 275-285.
18. Pittaway DE, Fayaz JA, Douglas JW, Serum CA-125 in the Evaluation of Benign Adnexal Cysts. Am J Obstet. Gynecol. 1987, 157, 1426-1428.
19. Molina R, Ballesta AM, Casals E, (et al.) Value of CA 125 Antigen as Tumour Marker: Preliminary Results In: Peeters H. ed. Protides of the Biological Fluids: Proceedings of the Thirty-second Colloquium. 1984, Oxford U.K. Pergamon Press, 1984, 613-616
20. Haga Y, Sakamoto K, Egami H (et al.) Evaluation of Serum CA 125 Values in Healthy Individuals and Pregnant Woman. Am J Med. Sci. 1986, 29(1), 25-29
21. Welsh J, Zarrinkar P, Sapinoso L, (et al.). Analysisi of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular of epithelial ovarian cancer. PNAS, 2001, 98, 3, 1176-1181.
22. Hibbs K, Skubitz K, Pambuccian S, (et al.) Differential Gene Expression in Ovarian Carcinoma. Am J. Pathol. 2004, 165,2, 397-414.
23. Kim JH, Skates SJ, Uede T, (et al.). Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287(13), 1671-1679.
24. Meinhold-Heerlein I, Bauerschalag D, Zhou Y, (et al.) An Integrated Clinical-Genomics Approach Identifies a Candidate Mult-Analyte Blood Test for Serous Ovarian Carcinoma. Clin Cancer Res. 2007, 13(2), 458-466
25. Schorge J, Drake R, Lee H, (et al.). Osteopontin as an Adjunct to CA 125 in Detecting Recurrent Ovarian Cancer. Clin. Cancer Res. 2004, 10, 3474-3478.
26. Nakae M, Iwamoto I, Fujino T. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynecol. Res. 2006, 32(3), 309-314.